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Abstract
Objective A multicentre study was conducted to investigate the impact of sarcopenia as an independent predictor of onco-
logical outcome after radical cystectomy for bladder cancer.
Methods In total, 500 patients with available digital computed tomography scans of the abdomen obtained within 90 days
before surgery were identiﬁed. The lumbar skeletal muscle index was measured using pre-operative computed tomography.
Cancer-speciﬁc survival (CSS) and overall survival (OS) were estimated using Kaplan–Meier curves. Predictors of CSS and OS
were analysed by univariable and multivariable Cox regression models.
Results Based on skeletal muscle index, 189 patients (37.8%) were classiﬁed as sarcopenic. Patients with sarcopenia were
older compared with their counterparts (P = 0.002), but both groups were comparable regarding to gender, comorbidity, tu-
mor, node, metastasis (TNM) stage, and type of urinary diversion (all P > 0.05). In total, 234 (46.8%) patients died, and of
these, 145 (29.0%) died because of urothelial carcinoma of the bladder. Sarcopenic patients had signiﬁcantly worse 5 year
OS (38.3% vs. 50.5%; P = 0.002) and 5 year CSS (49.5% vs. 62.3%; P = 0.016) rates compared with patients without sarcopenia.
Moreover, sarcopenia was associated independently with both increased all-cause mortality (hazard ratio, 1.43; 95% conﬁ-
dence interval 1.09–1.87; P = 0.01) and increased cancer-speciﬁc mortality (hazard ratio, 1.42; 95% conﬁdence interval,
1.00–2.02; P = 0.048). Our results are limited by the lack of prospective frailty assessment.
Conclusions Sarcopenia has been shown to be an independent predictor for OS and CSS in a large multicentre study with
patients undergoing radical cystectomy for bladder cancer.
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Introduction
Radical cystectomy (RC) with bilateral pelvic lymph node dis-
section is the gold-standard treatment for muscle invasive
urothelial carcinoma of the bladder (UCB) and for high-risk
non-muscle invasive UCB resistant to intravesical therapy.1,2
Despite curative intent, RC only provides 5 year overall sur-
vival (OS) rates of approximately 60%.1,2 Besides
histopathological characteristics, comorbidity has also been
shown to affect patient outcome after RC.3,4
Frailty is deﬁned as a clinical syndrome suggesting de-
creased physiological reserve.5 Sarcopenia is the paucity of
muscle mass, which is a key component of frailty.6 Muscle
mass decrease is directly responsible for functional impair-
ment with loss of strength, increased likelihood of falling,
and loss of autonomy.7
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Sarcopenia has already been investigated in different tu-
mour entities. So far, sarcopenia was identiﬁed as a poor
prognostic factor in patients undergoing surgical treatment
for tumours of the respiratory tract, gastrointestinal tract,
malignant melanoma, UCB, and upper urinary tract urothelial
carcinoma.8–13 Furthermore, sarcopenia has been shown to
be an independent prognostic factor of survival after RC for
UCB, and it was strongly associated with early complications
following RC.11,13,14 However, only single-centre studies with
limited patient numbers or inadequate sarcopenia classiﬁca-
tions are available.11,13
The aim of our study was to assess the prevalence of ade-
quately assessed sarcopenia in a large multicentre study and
to investigate its association with OS and cancer-speciﬁc sur-
vival (CSS) in patients undergoing RC for UCB.
Patients and methods
Patients
After Institutional Review Board approval and obtaining
ethics approval, 860 patients who underwent RC for UCB at
three tertiary institutions between 2004 and 2014 were ret-
rospectively identiﬁed. In 709 patients, computed tomogra-
phy (CT) of the abdomen was performed as pre-operative
staging, 142 were not available as digital ﬁle, 33 were not
performed within 90 days prior to RC, and 32 patients had
to be excluded because of poor image quality. Of 860 pa-
tients, seven patients had neoadjuvant chemotherapy (NAC)
prior to RC, of whom four patients did not have a CT after
completion of NAC. Three patients had a CT after NAC, but
only two were available as digital ﬁle. Because of the small
number, inhomogeneity of this subgroup and risk of con-
founding, patients who underwent NAC were excluded. The
ﬁnal study cohort consisted of a total of 500 patients.
All tumours were histologically conﬁrmed as UCB. Tumour
staging was performed according to the seventh edition
of the American Joint Committee on Cancer/Union
Internationale Contre le Cancer TNM classiﬁcation.15
Follow-up regimens were conducted according to institu-
tional protocols. The cause of death was determined by chart
review. A patient with metastatic disease at the time of death
was categorized as having died of disease.
Pre-operative computed tomography-based muscle
measurement
Sarcopenia was determined by a surrogate marker: the cross-
sectional skeletal muscle surface (cm2) at the level of the
third lumbar vertebra (L3) on two consecutive transversal
CT images on which both vertebral spines were visible.16
Computed tomography images were contrast enhanced or
unenhanced 3- to 5-mm-thick multiplanar reconstructions
on the axial plane. Of note, the partial volume effect can be
neglected because of the almost cylindrical expansion of
the musculature. Measurements were performed using
Osirix™ version 7.0 (32 bit; http://www.osirix-viewer.com).
The ‘Grow Region (2D/3D Segmentation)’ tool was used to
automatically select all skeletal muscle mass in one transver-
sal CT image. The distinction between different tissues is
based on Hounsﬁeld units. A threshold range of 30 to
+110 Hounsﬁeld units was used for skeletal muscle.16
Muscles measured were the psoas, paraspinal, transverse ab-
dominal, external oblique, internal oblique, and rectus
abdominis muscles (Figure 1A and 1B). Manual adjustment
of the selected areas was performed if necessary. The aver-
ages of the two measurements were used for calculations.
Sarcopenia
Muscle area (cm2) was normalized for height in metres
squared (m2) and reported as lumbar skeletal muscle index
(SMI) (cm2/m2) According to Martin et al.8, sarcopenia was
deﬁned as SMI of <43 cm2/m2 for men with body mass index
(BMI) <25 kg/m2, SMI <53 cm2/m2 for men with BMI
≥25 kg/m2, and SMI <41 cm2/m2 for women.
Comorbidity assessment
Comorbidity was assessed based on the information from pa-
tients’ ﬁles according to the Adult Comorbidity Evaluation 27
(ACE-27), which is a validated 27-item comorbidity instru-
ment for patients undergoing RC for UCB.3,17
Statistical analysis
Frequencies are presented as absolute numbers and percent-
ages. Continuous data are presented as median with inter-
quartile range (IQR). Differences between groups were
analysed using the Pearson’s χ2 test for dichotomous param-
eters and the Wilcoxon–Mann–Whitney U test for continuous
data. Survival analysis was performed with Kaplan–Meier and
Cox regression analyses. Hazard ratios (HRs) and 95% conﬁ-
dence intervals (CIs) were calculated by univariable and mul-
tivariable Cox regression analyses. For the calculation of
signiﬁcant predictors of survival, univariable analyses with
clinically relevant parameters were performed. Signiﬁcant
predictors (P < 0.05) based on univariable analyses were in-
cluded into a multivariable Cox regression analysis. P-values
<0.05 were considered signiﬁcant. To assess the validity of
the Cox models, the proportional hazards assumption of each
predictor variable was veriﬁed by using the Grambsch–
Therneau residual-based test.18 The type of relationship
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between SMI and OS was tested by restricted cubic splines
with 5 knots at percentiles 5%, 27.5%, 50%, 72.5% and 95%
as suggested by Frank Harrell in a multivariable Cox regres-
sion model.19 Optimal stratiﬁcation, a statistical method sim-
ilar to receiver operator curve analysis, was used to solve
speciﬁc threshold values for SMI. Optimal stratiﬁcation is
based on log-rank statistics that best separate patients with
respect to time to death.20 Skeletal muscle index thresh-
olds were already published by Martin et al.8, but these
values were solved in a cohort of 1.473 patients with a di-
agnosis of gastrointestinal or respiratory tract cancer, of
whom 50% had metastatic disease. In our study, we de-
ﬁned threshold values related to OS for SMI, and thresh-
olds for SMI were examined by sex and BMI and
compared with the existing cut-offs. Cox regression analy-
ses were carried out with the threshold values published
by Martin et al.8 Statistical analyses were conducted with
SAS (version 9.4; SAS Institute, Cary, NC, USA) and R 3.2.2
for Windows (R Foundation for Statistical Computing,
Vienna, Austria; http://www.r-project.org/).
Results
The median SMI among women in the study cohort was
42.3 cm2/m2 (IQR, 38.1–48.1 cm2/m2), whereas the median
SMI in men was 52.2 cm2/m2 (IQR, 46.8–58.1 cm2/m2). The
overall prevalence of sarcopenia in the study population was
37.8% (189/500 patients), including 43.4% of women (43/99)
and 36.2% of men (145/401). Sarcopenic patients were signif-
icantly older (median pre-operative age of 73 vs. 70 years;
P = 0.002) but were otherwise similar regarding to comorbidity
(ACE-27), TNM stage, urinary diversion, lymphovascular inva-
sion (LVI), carcinoma in situ, days between CT and surgery, ad-
ministration of adjuvant chemotherapy, and soft tissue
surgical margins (P> 0.05 for all, Table 1). In addition, median
BMI was signiﬁcantly lower in sarcopenic patients compared
with their counterparts (26.0 vs. 27.0 kg/m2; P < 0.001).
Patient characteristics are depicted in Table 1.
Calculated threshold values for SMI associated with lower
survival in the current cohort are listed in Table 2. Spline
curves of adjusted HR for OS show a linear correlation be-
tween 48 and 55 cm2/m2, while in the lower and upper
quartiles, a change of SMI shows no further effect on OS
(Figure 2). The calculated threshold values from the current
cohort differed only to a little extent to the published thresh-
old values from Martin et al.8 (Table 2).
The median follow-up for survivors was 35 months (IQR,
20–58 months). The median overall follow-up of patients
was 22 months (IQR, 10–45 months). Two hundred thirty-
four (46.8%) patients died, with 145 (29%) of these dying
because of UCB. In addition, patients with sarcopenia had a
signiﬁcantly decreased 5 year OS (38.3% vs. 50.5%,
P = 0.002, Figure 3A) and CSS (49.5% vs. 62.3%, P = 0.016,
Figure 3B) compared with non-sarcopenic patients.
Figure 1 (A and B) Axial computed tomography images at the third lumbar vertebra region with skeletal muscle highlighted in orange. (A1–A3) depict
variation in skeletal muscle index (SMI) for male patients with identical body mass indices (BMIs) (24.7 kg/m2) and different SMIs. (B1–B3) depict var-
iation in BMI for sarcopenic female patients (SMI of 40.7 cm2/m2) and different BMIs. The orange regions represent the skeletal muscle, identiﬁed by
attenuation limits of 29 to 110 Hounsﬁeld units. The SMI is calculated by dividing the cross-sectional area of skeletal muscle (cm2) by the patient’s
height squared (m2).
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In univariable analysis, age, sarcopenia, higher ACE-27,
higher pathological tumour (pT) stage, lymph node metasta-
sis, LVI, positive surgical margins, and adjuvant chemotherapy
were signiﬁcantly associated with decreased OS and CSS after
RC for UCB (Tables 3 and 4). In the multivariable Cox regres-
sion analysis, age, comorbidity (ACE-27), pathological tumour
and nodal stage, LVI, surgical margin rates, and administra-
tion of adjuvant chemotherapy as additional covariates, the
presence of sarcopenia remained signiﬁcantly associated with
increased all-cause mortality after RC (HR, 1.43; 95% CI 1.09–
1.87; P = 0.01). This model provides a c-index of 0.754. The
same multivariable model with the SMI cut-offs derived from
our cohort provides a c-index of 0.760. In addition,
sarcopenia was also signiﬁcantly associated with increased
cancer-speciﬁc mortality (HR, 1.42; 95% CI, 1.00–2.02;
P = 0.048) after adjusting for age, ACE-27, pathological tu-
mour and nodal stage, LVI surgical margin rates after RC,
and administration of adjuvant chemotherapy (Table 4). The
Table 1 Patient characteristics of sarcopenic and non-sarcopenic patients
Variables Entire cohort (n = 500)
Sarcopenic
patients (n = 189)
Non-sarcopenic
patients (n = 311) P-value
Median age at RC (IQR) 72 (65.00–78.00) 73 (66–79) 70 (63–77) 0.002
Male, n (%) 401 (80.2) 146 (77.25) 255 (82.0) 0.197
Days between CT and RC, median (IQR) 18 (8–33) 16 (6–33) 20 (10–33) 0.110
Median BMI (kg/m2) (IQR) 26.3 (23.7–29.4) 26.0 (23.2–27.9) 27.0 (23.8–30.5) <0.001
Underweight (<20.00) 26 (5.2) 17 (9.0) 9 (2.9) <0.001
Normal weight (20.00–24.99) 160 (32.0) 51 (27.0) 109 (35.0)
Overweight (25.00–29.99) 207 (41.4) 103 (54.5) 104 (33.4)
Obese (>29.99) 107 (21.4) 18 (9.5) 89 (28.6)
ACE-27, n (%); missing n = 3
ACE-27: 0 (no comorbidity) 104 (20.9) 39 (20.6) 65 (21.1) 0.737
ACE-27: 1 (mild comorbidity) 154 (31.0) 64 (33.9) 90 (29.2)
ACE-27: 2 (moderate comorbidity) 143 (28.8) 51 (27.0) 92 (29.9)
ACE-27: 3 (severe comorbidity) 96 (19.3) 35 (18.5) 61 (19.8)
Urinary diversion, n (%)
Ileal conduit 249 (49.8) 85 (45.0) 164 (52.7) 0.236
Colon conduit 52 (10.4) 21 (11.1) 31 (10.0)
Ileal neobladder 131 (26.2) 50 (26.5) 81 (26.0)
Sigmoid neobladder 19 (3.8) 10 (5.3) 9 (2.9)
Pouch 15 (3.0) 5 (2.6) 10 (3.2)
Ureterocutaneostomy 34 (6.8) 18 (9.5) 16 (5.1)
Pathological tumour stage, n (%)
pTa 3 (0.6) 1 (0.6) 2 (0.6) 0.753
pTis 28 (5.6) 9 (4.8) 19 (6.1)
pT1 66 (13.2) 29 (15.3) 37 (11.9)
pT2 179 (35.8) 63 (33.3) 116 (37.3)
pT3 161 (32.2) 65 (34.4) 96 (30.9)
pT4 63 (12.6) 22 (11.6) 41 (13.2)
Pathological nodal classiﬁcation, n (%)
pN0 368 (73.6) 140 (74.1) 228 (73.3) 0.985
pN1 45 (9.0) 16 (8.5) 29 (9.3)
pN2 67 (13.4) 25 (13.2) 42 (13.5)
pN3 4 (0.8) 2 (1.1) 2 (0.6)
pNx 16 (3.2) 6 (3.2) 10 (3.2)
Presence of carcinoma in situ, n (%) 171 (34.2) 61 (32.3) 110 (35.4) 0.479
Presence of lymphovascular invasion, n (%) 200 (40.0) 73 (38.6) 127 (40.8) 0.624
Soft tissue surgical margin
R0 453 (90.6) 168 (88.9) 285 (91.6)
R1 41 (8.2) 18 (9.5) 23 (7.4) 0.569
R2 6 (1.2) 3 (1.6) 3 (1.0)
Adjuvant chemotherapy, n (%) 65 (13.0) 21 (11.1) 44 (14.1) 0.328
RC, radical cystectomy; IQR, interquartile range; BMI, body mass index; ACE-27, Adult Comorbidity Evaluation 27; CT, computed
tomography.
Table 2 Skeletal muscle index threshold values signiﬁcantly associated
with low overall survival in the current study cohort and the cohort of
Martin et al.8
BMI (kg/m2)
Current study cohort Martin et al.8
SMI (cm2/m2) SMI (cm2/m2)
Men Women Men Women
<25 48 40 43 41
≥25 52 43 53 41
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multivariable model regarding CSS provides a c-index of
0.802, and the multivariable model with our SMI cut-offs pro-
vides a c-index of 0.801. No violations of the proportional
hazards assumption and the linearity assumption were found.
Discussion
The aim of the present study was to assess the frequency of
sarcopenia and determine its impact on survival in a large
multicentre cohort of patients undergoing RC for UCB. We
deﬁned sarcopenia by sex-speciﬁc and BMI-speciﬁc threshold
values according to the Martin criteria, which were deter-
mined from 1473 cancer patients using optimal stratiﬁcation
of lower survival and therefore represents the most accurate
CT-derived sarcopenia classiﬁcation.8
Thirty-seven per cent of the patients in our cohort were
classiﬁed as sarcopenic. In a recently published Japanese
single-centre study of 136 patients undergoing RC for UCB,
65 patients (47.8%) were classiﬁed as sarcopenic.13 Although
in both cohorts sarcopenia has been classiﬁed according to
the Martin criteria, differences in sarcopenia frequencies
might be explained because of the retrospective and non-
consecutive fashion of the cohorts. In contrast, Psutka
et al.11 reported a study of 205 patients, of whom 141 pa-
tients (68.8%) were sarcopenic according to the criteria de-
ﬁned by Fearon et al.6 The applied classiﬁcation by Psutka
et al.11 has two important drawbacks: ﬁrst, the used CT-based
threshold values were converted from dual energy X-ray ab-
sorptiometry based threshold values, which were deﬁned as
values two standard deviations below the sex-speciﬁc means
in young healthy adults. This conversion was based on only
31 patients, who underwent both dual energy X-ray
absorptiometry and CT.21,22 Second, the threshold values
were not BMI speciﬁc. The threshold values reported from
Martin et al.8 (Table 2) were calculated from a large patient
cohort with a diagnosis of gastrointestinal and respiratory
tract cancer, of whom 50% had metastatic disease. To inves-
tigate whether these established SMI threshold values are
suitable for non-metastatic bladder cancer patients, SMI
threshold values from our cohort were calculated, which dif-
fered only to a little extent compared with the established
values from Martin et al.8 (Table 2). In addition, the predic-
tive capacity for OS and CSS showed only a minimal improve-
ment and conﬁrms the applicability in bladder cancer
patients.
The most important ﬁnding in the current study is the in-
dependent association of sarcopenia and increased cancer-
speciﬁc mortality (HR, 1.42; 95% CI, 1.00–2.02; P = 0.048)
and increased all-cause mortality (HR, 1.43; 95% CI
1.09–1.87; P = 0.01). These results are in concordance with
the previous published literature. Psutka et al.11 were able
to demonstrate that sarcopenia was an independent predic-
tor of CSS (HR 2.14; 95% CI 1.24–3.71; P = 0.007) and OS
(HR 1.93; 95% CI 1.23–3.00; P = 0.004). Hirasawa et al.13 dem-
onstrated that sarcopenia was an independent predictor of
CSS in a single-centre cohort of 136 patients (HR 2.3; 95%
CI 1.2–4.4; P = 0.015). However, this study was limited by a
small sample size and a small number of events (n = 42),
and therefore, an overﬁtting bias in the multivariate analysis
must be taken into account. In contrast, a study reported by
Smith et al.10 including 200 patients undergoing RC for UCB
could not demonstrate an association between survival and
sarcopenia, which was classiﬁed by the total psoas area.
However, their study was limited by a median follow-up of
16 months, and sarcopenia was assessed by total psoas area,
which is lacking validated threshold values. Even in metasta-
tic UCB, sarcopenia was shown to be an independent predic-
tor of poor CSS (HR 2.07; 95% CI 1.01–4.67; P = 0.045).23
Comorbidity indices such as the ACE-27 score and the
Charlson comorbidity index have been evaluated as predic-
tors for survival after RC for UCB.3,4 Our ﬁndings clearly dem-
onstrate that sarcopenia is an important predictor of survival
in UCB independent of the degree of comorbidity. Assess-
ment of sarcopenia by calculation of SMI is quick and simple
using free software and CT images without special training.
Furthermore, sarcopenia is a highly objective measure be-
cause one can estimate the composition of the human body
using CT with a precision error of 1.4%.24
Sarcopenia has important implications for clinical prac-
tice, because the decline of skeletal muscle mass is poten-
tially reversible.25 Adequate calorie and protein intake,
combined with resistance training, are the key components
in the management of sarcopenic patients.26,27 A prospec-
tive Japanese single-centre study demonstrated that
sarcopenic patients older than 65 years undergoing gastrec-
tomy for gastric cancer had signiﬁcantly lower caloric and
Figure 2 Restricted cubic spline with 5 knots at percentiles 5%, 27.5%,
50%, 72.5%, and 95% (vertical dotted lines) showing the relationship be-
tween skeletal muscle index (SMI) (cm2/m2) and hazard ratios of overall
survival (red line). Ninety-ﬁve per cent conﬁdence interval is indicated by
the dotted blue lines. The model is adjusted for signiﬁcant covariates
depicted in Table 3.
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protein intake per day and had signiﬁcantly more severe
complications.28 Interestingly, the same research group in-
vestigated 22 sarcopenic patients undergoing gastrectomy
for gastric cancer and established a pre-operative exercise
and nutritional support programme, which resulted in a sig-
niﬁcantly higher calorie and protein intake per day and in-
creased handgrip strength.29 In addition, four of the 22
investigated patients became non-sarcopenic after the
support programme. In the previously mentioned study by
Hirasawa et al.,13 it was demonstrated that sarcopenic pa-
tients showed signiﬁcantly lower haemoglobin levels than
non-sarcopenic patients. As recently shown in a random-
ized controlled trial, patients with iron-deﬁciency anaemia
undergoing major open abdominal surgery showed signiﬁ-
cantly reduced blood transfusions and length of hospital
stay, when administered perioperative intravenous iron.30
Figure 3 (A and B) Kaplan–Meier plots depicting overall survival and cancer-speciﬁc survival in sarcopenic and non-sarcopenic patients undergoing
radical cystectomy for urothelial carcinoma of the bladder.
A
B
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Perioperative iron transfusion could therefore complement
the nutritional support programme in sarcopenic patients
with iron-deﬁciency anaemia. In addition, the prevention
of muscle loss is a necessary precondition for autonomy
for older people. Food supplements with proteins, leucine,
vitamin D, and antioxidants delay progression of sarcopenia
and also stimulate muscular protein synthesis.31,32 Alterna-
tively, anabolic hormones such as testosterone, oestrogen,
and growth factors can play a role in the prevention, delay,
and regression of sarcopenia.32
Table 3 Univariate and multivariable Cox regression models addressing prediction of overall survival after radical cystectomy for urothelial carcinoma
of the bladder
Variables
Univariate analysis Multivariable analysis
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age at RC (continous) 1.043 1.03–1.06 <0.001 1.03 1.01–1.04 0.002
Gender (reference: male) 1.28 0.94–1.74 0.123 — — —
Presence of sarcopenia (reference: absence) 1.50 1.16–1.94 0.002 1.43 1.09–1.87 0.01
pT stage
pT2 (reference: ≤pT1) 1.12 0.71–1.78 0.633 0.98 0.61–1.58 0.94
pT3 (reference: ≤pT1) 3.36 2.19–5.14 <0.001 1.95 1.22–3.14 0.006
pT4 (reference: ≤pT1) 4.46 2.78–7.17 <0.001 2.11 1.20–3.70 0.009
Presence of CIS (reference: absence) 0.78 0.59–1.02 0.071 — — —
Presence of LVI (reference: absence) 2.86 2.20–3.72 <0.001 1.72 1.25–2.38 0.001
Positive soft tissue surgical margin (reference: negative) 4.39 3.14–6.147 <0.001 2.41 1.63–3.55 <0.001
pN stage
pN+ (reference: pN0) 3.15 2.39–4.14 <0.001 1.73 1.24–2.41 0.001
pNx (reference: pN0) 2.90 1.60–5.24 <0.001 1.81 0.98–3.34 0.056
ACE-27
ACE-27: 1 (reference: ACE-27 0) 1.22 0.81–1.84 0.333 1.14 0.76–1.70 0.526
ACE-27: 2 (reference: ACE-27 0) 1.60 1.08–2.37 0.019 1.56 1.04–2.34 0.033
ACE-27: 3 (reference: ACE-27 0) 1.60 1.08–2.37 0.004 1.75 1.12–2.73 0.013
Adjuvant chemotherapy (reference: not administered) 1.64 1.17–2.28 0.004 0.83 0.55–1.23 0.347
Body mass index
Underweight (reference: normal weight) 0.80 0.59–1.08 0.140 — — —
Overweight (reference: normal weight) 0.81 0.57–1.16 0.258 — — —
Obese (reference: normal weight) 1.15 0.65–2.03 0.625 — — —
CI, conﬁdence interval; RC, radical cystectomy; CIS, carcinoma in situ; LVI, lymphovascular invasion; ACE-27, Adult Comorbidity Evaluation 27.
Table 4 Univariate and multivariable Cox regression models addressing the prediction of cancer-speciﬁc survival after radical cystectomy for urothelial
carcinoma of the bladder
Variables
Univariate analysis Multivariable analysis
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age at RC (continous) 1.03 1.01–1.05 0.002 1.01 0.99–1.033 0.206
Gender (reference: male) 1.32 0.89–1.96 0.163 — — —
Presence of sarcopenia (reference: absence) 1.49 1.07–2.07 0.018 1.42 1.00–2.02 0.048
pT stage
pT2 (reference: ≤pT1) 1.64 0.80–3.35 0.184 1.33 0.64–2.77 0.442
pT3 (reference: ≤pT1) 6.71 3.46–13.02 <0.001 3.54 1.73–7.24 0.001
pT4 (reference: ≤pT1) 8.57 4.20–17.46 <0.001 3.20 1.41–7.27 0.005
Presence of CIS (reference: absence) 0.78 0.55–1.11 0.164 — — —
Presence of LVI (reference: absence) 3.72 2.65–5.22 <0.001 1.81 1.20–2.73 0.005
Positive soft tissue surgical margin (reference: negative) 5.89 3.92–8.83 <0.001 3.24 2.01–5.23 <0.001
pN stage
pN+ (reference: pN0) 4.14 2.95–5.81 <0.001 1.79 1.19–2.70 0.005
pNx (reference: pN0) 2.57 1.12–5.91 0.026 1.75 0.74–4.15 0.202
ACE-27
ACE-27: 1 (reference: ACE-27 0) 1.15 0.70–1.89 0.588 1.13 0.68–1.89 0.639
ACE-27: 2 (reference: ACE-27 0) 1.34 0.82–2.20 0.249 1.49 0.90–2.50 0.130
ACE-27: 3 (reference: ACE-27 0) 1.74 1.04–2.92 0.036 1.81 1.03–3.17 0.039
Adjuvant chemotherapy (reference: not administered) 2.72 1.87–3.94 <0.001 1.11 0.70–1.75 0.67
Body mass index
Underweight (reference: normal weight) 0.85 0.59–1.24 0.394 — — —
Overweight (reference: normal weight) 0.75 0.47–1.19 0.221 — — —
Obese (reference: normal weight) 0.79 0.34–1.84 0.587 — — —
CI, conﬁdence interval; RC, radical cystectomy; CIS, carcinoma in situ; LVI, lymphovascular invasion; ACE-27, Adult Comorbidity Evaluation
27; BMI, body mass index.
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To the best of our knowledge, this is the largest and ﬁrst
multicentre study (n = 500) reporting sarcopenia as a prog-
nostic factor in patients undergoing RC, classifying sarcopenia
according to the Martin criteria.8 A further strength of the
current paper is that the multivariate model was adjusted
for comorbidity, which is an independent predictor of survival
after RC for UCB.3 In our analyses, ACE-27 was used as quan-
tiﬁcation tool for comorbidity, as it is the most accurate co-
morbidity index and it has been robustly evaluated in
17 712 cancer patients.17
Our study is not free of limitations. In this survey, we col-
lected data from 500 patients in a non-consecutive fashion
due to its retrospective nature. In addition, the current study
was limited by the ﬁnding that many of the patients who
underwent RC during 2004–2014 did not have digital CT
scans available for SMI analysis and therefore were excluded
from the ﬁnal analysis. Given its retrospective nature, we
were unable to correlate SMI with other metrics of frailty
such as performance status on patient questionnaires or
walking speed or grip strength tests and nutritional status.
To overcome this limitation, a prospective multicentre study
should be performed to acquire a consecutive patient cohort
with a prospective frailty assessment. However, the assess-
ment of skeletal muscle mass was not limited because of
the prospective acquisition of CT images. A further notable
limitation of the study is the reduced frequency of patients
undergoing NAC, which have therefore not been included in
the ﬁnal analysis. Even though NAC frequencies of 20% have
been reported in the USA in 2010, a prospective European RC
study from 2011 demonstrated frequency rates of 2%, which
is in concordance with our study.33,34 However, to investigate
the impact of sarcopenia in patients undergoing NAC, further
studies are needed.
Taken together, sarcopenia is an objective risk factor for
prediction of CSS and OS in patients with UCB undergoing
RC. The identiﬁcation of patients with sarcopenia is impor-
tant as their outcome may be improved by pre-operative ex-
ercise and nutritional support programmes prior to RC.
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